Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

teaman60 Apr. 1 at 6:53 PM

$RLMD Too bad couldn't hold the gain today. Will close under 7 I believe

1 · Reply

shehww Apr. 1 at 1:42 PM

$RLMD 8+ 🔥🔥🔥🚀🚀🚀💥💥💥🔥🔥🔥

0 · Reply

shehww Mar. 31 at 7:44 PM

$RLMD soon $8+

0 · Reply

shehww Mar. 30 at 3:09 PM

$RLMD

0 · Reply

shehww Mar. 25 at 2:19 PM

$RLMD 😎 🔥🔥🔥💥💥💥🚀🚀🚀

0 · Reply

AStrokeOfLuck Mar. 24 at 6:37 PM

$RLMD

0 · Reply

shehww Mar. 24 at 4:26 PM

$RLMD 😂

0 · Reply

teaman60 Mar. 23 at 6:32 PM

$RLMD low 5s by April 1

0 · Reply

shehww Mar. 23 at 4:58 PM

$RLMD

0 · Reply

IN0V8 Mar. 20 at 4:10 PM

$RLMD Watch / Opportunity Mizuho raises target price to $19 from $10

0 · Reply

Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript

Mar 19, 2026, 4:01 PM EDT - 17 days ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Mar 12, 2026, 7:00 AM EDT - 24 days ago

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Mar 9, 2026, 4:30 PM EDT - 27 days ago

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Mar 9, 2026, 7:05 AM EDT - 27 days ago

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Mar 9, 2026, 7:00 AM EDT - 27 days ago

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Jan 12, 2026, 7:00 AM EST - 2 months ago

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Dec 3, 2025, 7:30 AM EST - 4 months ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Nov 13, 2025, 7:21 PM EST - 5 months ago

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 5 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 5 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 4, 2025, 7:09 AM EST - 5 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 5 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Oct 7, 2025, 7:30 AM EDT - 6 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 16, 2025, 9:00 AM EDT - 7 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 7 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 8, 2025, 1:55 PM EDT - 8 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 8 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 9 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 9 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 10 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 10:02 PM EDT - 11 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 11 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 11 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 1:38 PM EDT - 1 year ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 1 year ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 1 year ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

teaman60 Apr. 1 at 6:53 PM

$RLMD Too bad couldn't hold the gain today. Will close under 7 I believe

1 · Reply

shehww Apr. 1 at 1:42 PM

$RLMD 8+ 🔥🔥🔥🚀🚀🚀💥💥💥🔥🔥🔥

0 · Reply

shehww Mar. 31 at 7:44 PM

$RLMD soon $8+

0 · Reply

shehww Mar. 30 at 3:09 PM

$RLMD

0 · Reply

shehww Mar. 25 at 2:19 PM

$RLMD 😎 🔥🔥🔥💥💥💥🚀🚀🚀

0 · Reply

AStrokeOfLuck Mar. 24 at 6:37 PM

$RLMD

0 · Reply

shehww Mar. 24 at 4:26 PM

$RLMD 😂

0 · Reply

teaman60 Mar. 23 at 6:32 PM

$RLMD low 5s by April 1

0 · Reply

shehww Mar. 23 at 4:58 PM

$RLMD

0 · Reply

IN0V8 Mar. 20 at 4:10 PM

$RLMD Watch / Opportunity Mizuho raises target price to $19 from $10

0 · Reply

anachartanalyst Mar. 20 at 2:01 PM

$RLMD https://anachart.com/wp-content/uploads/ana_temp/1774015290_soc-img.jpg

0 · Reply

shehww Mar. 20 at 1:55 PM

$RLMD next stop 8+

0 · Reply

teaman60 Mar. 19 at 11:03 PM

$RLMD as I have said previously,this company will never be able to get their drug to market. They will have to sell their rights to a big pharma

0 · Reply

teaman60 Mar. 19 at 10:28 PM

$RLMD this will dump hard at opening

1 · Reply

StocktwitsEarnings Mar. 19 at 9:14 PM

$RLMD Q4 '25 Earnings Results & Recap Relmada Therapeutics Inc. reported a net loss of $57,385,163, or $1.45 per common share, for the year ended December 31, 2025, and had negative operating cash flows of $45,786,988.

0 · Reply

shehww Mar. 19 at 8:29 PM

$RLMD very positiv news 💪🔥💥💥🔥

2 · Reply

CrestFresh Mar. 19 at 2:42 PM

$RLMD earnings AH?

0 · Reply

shehww Mar. 17 at 9:23 PM

$RLMD

0 · Reply

Sowa5000 Mar. 13 at 2:43 PM

$PALI $RLMD $IBRX $SLS Some winners here I will be buying and holding! Get them while they are cheap!

1 · Reply

teaman60 Mar. 13 at 2:17 PM

$RLMD Uh oh, zacks shorting this. Always a bad sign

0 · Reply

ZacksResearch Mar. 12 at 5:34 PM

$RLMD surges 42% in a week — what's fueling the rally? 🚀 Positive interim data from RLMD's phase II study shows a 76% 12-month complete response rate for NMIBC patients, with an 80% rate in the BCG-unresponsive subgroup. The candidate demonstrated strong durability and favorable safety, setting the stage for a phase III RESCUE program targeting two NMIBC settings. Discover the full potential of RLMD's NDV-01 here 👉 https://www.zacks.com/stock/news/2883316/rlmd-stock-surges-42-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2883316-body-37238&ADID=SYND_STOCKTWITS_TWEET_2_2883316_BODY_37238

0 · Reply

ZacksResearch Mar. 12 at 4:34 PM

$RLMD just ripped 42% in a week — and the catalyst is clinical data. 🚀 Relmada Therapeutics reported encouraging efficacy and safety results from a mid-stage bladder cancer study of NDV-01 and simultaneously outlined plans for a phase III trial. See what’s driving the momentum 👉 https://www.zacks.com/stock/news/2883316/rlmd-stock-surges-42-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2883316-teaser-37226&ADID=SYND_STOCKTWITS_TWEET_2_2883316_TEASER_37226

0 · Reply

Market Cap	733.18M
Revenue (ttm)	0.00
Net Income (ttm)	-57.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,846,100
Avg Vol	1,806,822
Day's Range	N/A - N/A
Shares Out	104.89M
Stochastic %K	78%
Beta	0.44
Analysts	Strong Sell
Price Target	$12.80